Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 233-343-1 | CAS number: 10124-56-8
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- abstract
- Justification for type of information:
- A scientific review.
Data source
Materials and methods
- Principles of method if other than guideline:
- Pregnant Wistar rats were treated via oral intubation with up to 1600 mg/kg Sodium Hexametaphosphate on days 6 to 15 of gestation.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Sodium metaphosphate
- EC Number:
- 233-343-1
- EC Name:
- Sodium metaphosphate
- Cas Number:
- 10124-56-8
- Molecular formula:
- Na6O18P6
- IUPAC Name:
- hexasodium 2,4,6,8,10,12-hexaoxocyclohexaphosphoxane-2,4,6,8,10,12-hexakis(olate)
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
Administration / exposure
- Route of administration:
- oral: gavage
Results and discussion
Any other information on results incl. tables
For pregnant rats given up to 240 mg/kg/day no effects on nidation, maternal survival, or fetal survival were observed. The incidence of skeletal or visceral abnormalities of the fetuses did not differ from that of controls.
Applicant's summary and conclusion
- Conclusions:
- For pregnant rats a given up to 240 mg/kg/day respectively, no effects on nidation, maternal survival, or fetal survival were observed. The incidence of skeletal or visceral abnormalities of the fetuses did not differ from that of controls.
- Executive summary:
Wistar rats were treated via oral intubation with up to 1600 mg/kg Sodium Hexametaphosphate on days 6 to 15 of gestation. For pregnant rats a given up to 240 mg/kg/day respectively, no effects on nidation, maternal survival, or fetal survival were observed.
The incidence of skeletal or visceral abnormalities of the fetuses did not differ from that of controls.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
